MSH is dedicated to expanding HIV prevention, care, and treatment to reach marginalized, hard-to-reach populations in the most affected countries. In 2019, our work in nine countries, Angola, Cameroon, Haiti, Mozambique, Nigeria, Rwanda, Tanzania, Uganda, and Ukraine, included the following results:

  • 343,983 Tested for HIV
  • 10,749 Newly diagnosed
  • 8,224 Newly initiated on antiretroviral therapy
  • 56,523 Maintained on antiretroviral therapy
  • 35,407 Virally suppressed

To enhance national HIV program sustainability, MSH works with governments and civil society to ensure greater country ownership of HIV programs and greater local technical and financial management of national HIV activities. 

  • In Nigeria, MSH improved testing efficiencies, linkage, and retention, as well as viral suppression, and strengthened the country’s public, private, and community sectors to deliver sustainable HIV and AIDS and TB services at 41 treatment centers in five states.  

We integrate sustainable and cost-effective HIV and AIDS services. 

  • In Malawi, where 80 percent of cervical cancer cases are fatal, we provided cervical cancer screening with antenatal and HIV services to stem the tide of the top cancer killer of women in low-income countries. 

  • In Uganda, Nigeria, and Angola, we mentored case managers, peer educators, counselors, and members of the local police force to identify signs of gender-based violence so that referrals can be made to health facilities and other institutions. 

We build public and private health-sector capacity to provide consistently available, quality HIV medicines by improving the collection and use of pharmaceutical supply chain data for forecasting and purchasing. 

  • In Uganda, we worked with the ministry of health to strengthen the supply chain system through stronger policies, strategies, and implementation capacity, resulting in increased access to essential medicines.

  • In Mozambique, the USAID MTaPS program (led by MSH) is establishing an active surveillance system to assess the safety of the dolutegravir-based antiretroviral medicine, an HIV drug in HIV/TB co-infected patients, including pregnant women. MTaPS is working with the national HIV program and the Directorate of Pharmacy, the agency responsible for regulating medicines and implementing pharmacovigilance, to monitor adverse or new reactions.

To advance global targets by 2020, MSH works with partners to identify people living with HIV and help enroll them in treatment. 

  • In Malawi, we used index case testing to successfully improve our efficiency in reaching those affected by HIV. 

  • In Angola, we partnered with peer educators to create support groups for sex workers, empowering them as leaders in HIV care and helping them fight discrimination and violence.

MSH Publications on HIV

This volume of 101 peer-reviewed journal articles highlights MSH’s long-term commitment to respond to the HIV epidemic and includes contributions from MSH staff, our national and international partners, and our donors. The papers present effective innovations for responding to the epidemic and make an important contribution to the evidence base of what works in HIV prevention, diagnosis, treatment, and treatment adherence, including systems strengthening innovations.

Read the bibliography

Technical Experts